Zenas BioPharma, Inc. (ZBIO) Balance Sheet
ZBIO balance sheet, 2025
December 31, 2025 · U.S. dollars$383.6M assets = $141.5M liabilities + $242.1M equity
Both columns are drawn to the same scale: what ZBIO owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ZBIO financial health
Descriptive bands, not a rating. Fiscal 2025.
ZBIO balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $74.6M2022 | $383.6M2025 | +72.6%/yr | |
| Total liabilities | $266.9M2022 | $141.5M2025 | −19.1%/yr | |
| Shareholders’ equity | −$192.3M2022 | $242.1M2025 | — | |
| Cash & short-term investments | $67.2M2022 | $343.2M2025 | +72.2%/yr | |
| Total debt | $1.5M2022 | $80.0M2025 | +274.1%/yr | |
| Net cash (debt) | $65.7M2022 | $263.2M2025 | +$197.5M | |
| Working capital | $42.5M2022 | $288.5M2025 | +$246.0M | |
| Book value per share | −$5.022022 | $5.412025 | — | |
| Current ratio | 2.642022 | 5.612025 | +2.97 | |
| Debt / equity | 0.002024 | 0.332025 | +0.33 | |
| Shares outstanding | 38.3M2022 | 44.7M2025 | +5.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ZBIO assets
ZBIO liabilities and equity
ZBIO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ZBIO balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $343.2M | $350.8M | $56.9M | $67.2M |
| Cash & equivalents | $110.6M | $319.7M | $56.9M | $67.2M |
| Short-term investments | $232.6M | $31.0M | $0 | — |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $8.0M | $5.2M | $2.9M | $1.2M |
| Total current assets | $351.2M | $355.9M | $59.8M | $68.4M |
| Property, plant & equipment (net) | $1.4M | $1.2M | $1.0M | $1.8M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 |
| Long-term investments | $17.3M | $0 | $0 | $0 |
| Other non-current assets | $13.8M | $12.9M | $7.4M | $4.3M |
| Total assets | $383.6M | $370.0M | $68.2M | $74.6M |
| Liabilities | ||||
| Accounts payable | $7.1M | $17.1M | $5.4M | $5.8M |
| Short-term debt | $1.1M | $785,000 | $556,000 | $715,000 |
| Total current liabilities | $62.6M | $57.3M | $23.3M | $26.0M |
| Long-term debt | $0 | $0 | $20.3M | $0 |
| Lease obligations | $1.3M | $1.0M | $813,000 | $1.5M |
| Other long-term liabilities | $78.8M | $218,000 | $250.3M | $240.9M |
| Total liabilities | $141.5M | $57.5M | $293.9M | $266.9M |
| Shareholders' equity | ||||
| Common stock & paid-in capital | $5,000 | $4,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$765.1M | −$387.4M | −$230.4M | −$193.3M |
| Accumulated other comprehensive income | −$64,000 | $194,000 | $37,000 | −$41,000 |
| Total shareholders' equity | $242.1M | $312.5M | −$225.7M | −$192.3M |
| Key figures | ||||
| Total debt | $80.0M | $1.0M | $21.1M | $1.5M |
| Net cash (debt) | $263.2M | $349.8M | $35.7M | $65.7M |
| Working capital | $288.5M | $298.6M | $36.5M | $42.5M |
| Tangible book value | $242.1M | $312.5M | −$225.7M | −$192.3M |
| Book value per share | $5.41 | $7.48 | −$5.89 | −$5.02 |
| Shares outstanding | 44.7M | 41.8M | 38.3M | 38.3M |
| Current ratio | 5.61 | 6.21 | 2.57 | 2.64 |
| Quick ratio | 5.48 | 6.12 | 2.44 | 2.59 |
| Debt / equity | 0.33 | 0.00 | — | — |
| Equity / assets | 63.1% | 84.5% | −331.1% | −257.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $643.1M | $717.2M | $343.2M | $290.9M | $273.3M | $312.4M | $350.8M | $386.8M | $183.9M | $37.2M | $56.9M | $72.3M |
| Cash & equivalents | $196.6M | $500.2M | $110.6M | $115.6M | $44.0M | $196.6M | $319.7M | $360.0M | $183.9M | $37.2M | $56.9M | $72.3M |
| Short-term investments | $446.5M | $217.0M | $232.6M | $175.3M | $229.3M | $115.8M | $31.0M | $26.8M | — | — | $0 | — |
| Receivables | $800,000 | $1.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $9.9M | $11.9M | $8.0M | $5.8M | $5.3M | $5.4M | $5.2M | $7.0M | $4.7M | $2.6M | $2.9M | $4.4M |
| Total current assets | $653.8M | $730.2M | $351.2M | $296.6M | $278.6M | $317.8M | $355.9M | $393.8M | $188.6M | $39.7M | $59.8M | $76.7M |
| Property, plant & equipment (net) | $844,000 | $1.1M | $1.4M | $857,000 | $1.1M | $1.3M | $1.2M | $545,000 | $706,000 | $847,000 | $1.0M | $1.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $30.8M | $1.3M | $17.3M | $10.7M | $1.6M | $1.8M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $16.3M | $15.1M | $13.8M | $13.8M | $11.8M | $12.8M | $12.9M | $9.1M | $10.6M | $8.5M | $7.4M | $6.0M |
| Total assets | $701.7M | $747.7M | $383.6M | $322.0M | $293.1M | $333.8M | $370.0M | $403.4M | $200.0M | $49.1M | $68.2M | $83.8M |
| Liabilities | ||||||||||||
| Accounts payable | $7.6M | $8.9M | $7.1M | $6.4M | $7.9M | $20.0M | $17.1M | $15.1M | $8.4M | $8.8M | $5.4M | $2.3M |
| Short-term debt | $823,000 | $1.0M | $1.1M | $618,000 | $793,000 | $908,000 | $785,000 | $384,000 | $494,000 | $516,000 | $556,000 | $583,000 |
| Total current liabilities | $65.8M | $61.2M | $62.6M | $52.4M | $53.2M | $49.1M | $57.3M | $44.0M | $39.1M | $30.3M | $23.3M | $15.6M |
| Long-term debt | $297.0M | $265.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $21.0M | $20.3M | $20.0M |
| Lease obligations | $845,000 | $1.1M | $1.3M | $798,000 | $1.0M | $1.2M | $1.0M | $384,000 | $508,000 | $649,000 | $813,000 | $964,000 |
| Other long-term liabilities | $91.8M | $85.0M | $78.8M | $73.2M | $215,000 | $317,000 | $218,000 | $0 | $14,000 | $250.2M | $250.3M | $250.5M |
| Total liabilities | $454.6M | $411.9M | $141.5M | $125.6M | $53.5M | $49.4M | $57.5M | $44.0M | $39.1M | $301.5M | $293.9M | $286.0M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $6,000 | $6,000 | $5,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$957.6M | −$846.1M | −$765.1M | −$524.7M | −$473.2M | −$421.0M | −$387.4M | −$334.8M | −$296.2M | −$258.2M | −$230.4M | −$205.8M |
| Accumulated other comprehensive income | −$1.1M | −$377,000 | −$64,000 | −$69,000 | −$94,000 | $141,000 | $194,000 | $54,000 | $104,000 | $74,000 | $37,000 | $124,000 |
| Total shareholders' equity | $247.1M | $335.8M | $242.1M | $196.4M | $239.6M | $284.3M | $312.5M | $359.4M | $160.8M | −$252.5M | −$225.7M | −$202.2M |
| Key figures | ||||||||||||
| Total debt | $389.6M | $351.7M | $80.0M | $798,000 | $1.0M | $1.2M | $1.0M | $384,000 | $508,000 | $21.6M | $21.1M | $21.0M |
| Net cash (debt) | $253.5M | $365.5M | $263.2M | $290.1M | $272.3M | $311.2M | $349.8M | $386.4M | $183.4M | $15.5M | $35.7M | $51.3M |
| Working capital | $588.0M | $669.0M | $288.5M | $244.2M | $225.4M | $268.7M | $298.6M | $349.8M | $149.5M | $9.4M | $36.5M | $61.1M |
| Tangible book value | $247.1M | $335.8M | $242.1M | $196.4M | $239.6M | $284.3M | $312.5M | $359.4M | $160.8M | −$252.5M | −$225.7M | −$202.2M |
| Book value per share | $3.92 | $6.04 | $5.21 | $4.66 | $5.72 | $6.80 | $7.48 | $8.60 | $4.20 | −$6.59 | −$5.89 | −$4.84 |
| Shares outstanding | 63.1M | 55.6M | 46.5M | 42.2M | 41.9M | 41.8M | 41.8M | 41.8M | 38.3M | 38.3M | 38.3M | 41.8M |
| Current ratio | 9.93 | 11.94 | 5.61 | 5.66 | 5.23 | 6.47 | 6.21 | 8.95 | 4.82 | 1.31 | 2.57 | 4.93 |
| Quick ratio | 9.78 | 11.74 | 5.48 | 5.55 | 5.13 | 6.36 | 6.12 | 8.79 | 4.70 | 1.22 | 2.44 | 4.65 |
| Debt / equity | 1.58 | 1.05 | 0.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Equity / assets | 35.2% | 44.9% | 63.1% | 61.0% | 81.8% | 85.2% | 84.5% | 89.1% | 80.4% | −514.8% | −331.1% | −241.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 16, 2026); data from EODHD.
ZBIO financial position
At the end of fiscal 2025 (December 31, 2025), Zenas BioPharma had total assets of $383.6 million (up 3.7% from a year earlier), total liabilities of $141.5 million and shareholders' equity of $242.1 million. It held $343.2 million in cash and short-term investments against $80.0 million of debt, a net cash position of $263.2 million. Its current ratio was 5.61. In the latest quarter (ended June 30, 2026) total assets were $701.7 million and equity $247.1 million.
Related: ZBIO income statement, ZBIO cash flow statement, ZBIO key metrics. See the ZBIO stock overview for the latest quote and news.
ZBIO balance sheet FAQ
What are Zenas BioPharma's total assets?
Zenas BioPharma reported total assets of $383.6 million at the end of fiscal 2025 (December 31, 2025), compared with $370.0 million a year earlier.
How much debt does Zenas BioPharma have?
Zenas BioPharma had $80.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.33.
How much cash does Zenas BioPharma have?
Zenas BioPharma held $343.2 million in cash and short-term investments at the end of fiscal 2025; with $80.0 million of debt that is net cash of $263.2 million.
What is Zenas BioPharma's book value?
Zenas BioPharma's shareholders' equity (book value) was $242.1 million at the end of fiscal 2025, or $5.41 per share.
What is Zenas BioPharma's current ratio?
Zenas BioPharma had current assets of $351.2 million and current liabilities of $62.6 million, a current ratio of 5.61 (it can cover its short-term obligations).